Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Roxadustat Combined With Retinoic Acid in Refractory Low-risk MDS
NCT06020833Phase 2Withdrawn
- Sponsor
- Peking Union Medical College Hospital
- Start
- Aug 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of roxadustat in myelodysplastic syndrome (MDS), sponsored by Peking Union Medical College Hospital. Planned start Aug 2023; status: withdrawn.
02
Drugs
roxadustat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT06020833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020833.